MABp1 for the treatment of colorectal cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. Epub 2011/03/08.
   PubMed Web of Science ®Google Scholar
• Dutta S, Crumley AB, Fullarton GM, et al. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861–1866. Epub 2011/05/04.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ning Z, Chen J, et al. Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Sci Rep. 2015;5:18811.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–1195. Epub 2013/01/30.
   PubMed Web of Science ®Google Scholar
• Sweis RF, Spranger S, Bao R, et al. Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4(7):563–568.
   PubMed Web of Science ®Google Scholar
• Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43–48.
   PubMed Web of Science ®Google Scholar
• Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–2087.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984;311(22):1413–1418.
   PubMed Web of Science ®Google Scholar
• Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med. 1972;136(1):143–155.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The interleukin-1 family: 10 years of discovery. Faseb J. 1994;8(15):1314–1325.
   PubMed Web of Science ®Google Scholar
• Mayer-Barber KD, Yan B. Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol. 2017;14(1):22–35.
   PubMed Web of Science ®Google Scholar
• Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20–38.
   PubMed Web of Science ®Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656–666.
   PubMed Web of Science ®Google Scholar
• Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25(3):387–408.
   PubMed Web of Science ®Google Scholar
• Pantschenko AG, Pushkar I, Anderson KH, et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003;23(2):269–284.
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100(5):2645–2650.
   PubMed Web of Science ®Google Scholar
• Dmitrieva OS, Shilovskiy IP, Khaitov MR, et al. Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry (Mosc). 2016;81(2):80–90.
   PubMed Web of Science ®Google Scholar
• Wang XS. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs. 2008;12(5 Suppl):11–20.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile MI, Rossi Fanelli F, et al. Novel therapeutic options for cachexia and sarcopenia. Expert Opin Biol Ther. 2016;16(10):1239–1244.
   PubMed Web of Science ®Google Scholar
• Gelfo V, Rodia MT, Pucci M, et al. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget. 2016;7(44):72167–72183.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. Epub 2014/11/02.
   PubMed Web of Science ®Google Scholar
• Garrone P, Djossou O, Fossiez F, et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Mol Immunol. 1996;33(7–8):649–658.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization general policies for monoclonal antibodies. 2009 [cited 2017 Jun]. Available from: http://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf
   Google Scholar
• Pottier J, Chastang R, Dumet C, et al. Rethinking the INN system for therapeutic antibodies. mAbs. 2017;9(1):5–11.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652.
   PubMed Web of Science ®Google Scholar
• Hong DS, Janku F, Naing A, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015;33(3):621–631. Epub 2015/03/31.
   PubMed Web of Science ®Google Scholar
• Carrasco D, Stecher M, Lefebvre GC, et al. An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity. J Drugs Dermatol. 2015;14(6):560–564. Epub 2015/06/20.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Menter A. Reporting of MABp1 for the treatment of psoriasis. JAMA Dermatology. 2015;151(10):1143–1144. Epub 2015/10/16.
   PubMed Web of Science ®Google Scholar
• El Sayed H, Kerensky R, Stecher M, et al. A randomized phase II study of Xilonix, a targeted therapy against interleukin 1alpha, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J Vasc Surg. 2016;63(1):133–41.e1. Epub 2015/10/05.
   PubMed Web of Science ®Google Scholar
• Timper K, Seelig E, Tsakiris DA, et al. Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. J Diabetes Complications. 2015;29(7):955–960. Epub 2015/07/04.
   PubMed Web of Science ®Google Scholar
• Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18(2):192–201.
   PubMed Web of Science ®Google Scholar
• Goel S,Wyrwicz L, Choi M et al. 2016 Gastrointestinal Cancer Symposium, Trials in Progress. Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer. J Clin Oncol. 2016;34:: 4_suppl, TPS784-TPS784).
   Google Scholar
• Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218–5224. Epub 2007/11/21.
   PubMed Web of Science ®Google Scholar
• Minasian LM, O’Mara AM, Reeve BB, et al. Health-related quality of life and symptom management research sponsored by the National Cancer Institute. J Clin Oncol. 2007;25(32):5128–5132.
   PubMed Web of Science ®Google Scholar
• Fallowfield LJ, Fleissig A. The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol. 2011;9(1):41–47.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007;97(11):1469–1474.
   PubMed Web of Science ®Google Scholar
• Chibaudel B, Bonnetain F, Shi Q, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy–an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011;29(31):4199–4204.
   PubMed Web of Science ®Google Scholar
• Provenzano A. The cross roads of clinical trials, the promise of personalized medicine, and surrogate endpoints: ‘To Boldly Go Where No Man Has Gone Before…’. ASCO connnection [Internet]; 2012 2017 Mar. Available from: https://connection.asco.org/magazine/current-controversies-oncology/clinical-trials-predictive-factors-and-endpoints-current-and
   Google Scholar
• Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40.
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114–122.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1alpha neutralisation in patients with cancer. Lancet Oncol. 2014;15(6):552–553.
   PubMed Web of Science ®Google Scholar
• Price TJ. Advanced colorectal cancer treatment options beyond standard systemic therapy. Lancet Oncol. 2017;18(2):157–159.
   PubMed Web of Science ®Google Scholar
• Campbell PT, Rebbeck TR, Nishihara R, et al. Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017;28(2):167–176.
   PubMed Web of Science ®Google Scholar